No clear path forward for secondary-progressive MS, says BioMS
This article was originally published in Scrip
Executive Summary
The recent discontinuation of Lilly/BioMS's dirucotide has left the late-stage pipeline for secondary-progressive multiple sclerosis empty, diminishing hopes of finding an effective treatment for the condition.